Javier Guodong Jia | CEO, OBIO Technology (Shanghai)Corp. Ltd. 

Javier Guodong Jia PhD, Lead 500 employees and manage 15 000m2 facility to provide CRO/CDMO service to gene and cell therapy clients. Has more than 90 GCT project experience in past 5 years, covering plasmid, LV, AAV, ADV, HSV, VV, CART cell. Is familiar with US and China GCT regulatory, and already supported 7 virus products IND in China and US.
Recently, Javier is leading OBiO team to build 77 000m2 GMP facility for GCT CDMO/CMO, estimated to start commercial GMP operation by the end of 2022. 
Before OBiO, Javier has worked in GE Healthcare Life Sciences (Cytiva, now) for 8 years, as China RD director, had very comprehensive experience in MAB, Vaccine and Plasma product process development. Javier is an expert on single use technology, process validation, DoE, QbD, HTPD, project management. 
Javier published 8 SCI papers, more than 10 patends, co editor for 2 CFDA regulatory handbooks, used to be Biopharma chairman in ISPE China committee.
Javier has a Ph.D degree on biochemical engineering, downstream purification background.